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Ovarian cancera b s t r a c t
Sprouty (SPRY) proteins are well-characterized factors that inhibit receptor tyrosine kinase
signaling. Our Human Exonic Evidence-Based Oligonucleotide (HEEBO) microarray results showed
that the mRNA levels of SPRY2, but not of SPRY1 or SPRY4, are down-regulated in high-grade serous
ovarian carcinoma (HGSC) tissues and epithelial ovarian cancer (EOC) cell lines. Molecular inversion
probe (MIP) copy number analysis showed the deletion of the SPRY2 locus in HGSC. Overexpression
of SPRY2 reduced EGF-induced cell invasion by attenuating EGF-induced E-cadherin down-regulation.
Moreover, a positive correlation between SPRY2 and E-cadherin protein levels was observed in HGSC
tissues. This study reveals the loss of SPRY2 in HGSC and indicates an important tumor-suppressive
role for SPRY2 in mediating the stimulatory effect of EGF on human EOC progression.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ovarian cancer is the ﬁfth leading cause of all female cancer-
related deaths and the most lethal gynecologic malignancy in
North America. Approximately 60% of women who develop ovarian
cancer will die from the disease [1,2]. Epithelial ovarian cancers
(EOCs) are divided into several histologic subtypes based on tumor
morphology [3]. The four major subtypes are serous, endometrioid,
clear cell and mucinous. Among these major subtypes, high-grade
serous carcinoma (HGSC) is the most common [4]. Although EOC
includes a majority of all ovarian carcinomas, its origin and etiol-
ogy have not yet been completely elucidated. It has been shown
that a malfunction of receptor tyrosine kinases (RTKs), including
epidermal growth factor receptor (EGFR), contributes to the devel-
opment of EOC [5]. EGFR and its ligands play a critical role in thestimulation of cancer cell proliferation, survival and metastasis
[6,7], and the overexpression of EGFR ligands has been detected
in human ovarian cancer tissue and ascitic ﬂuid [8,9]. Moreover,
EGFR levels were found to be up-regulated in the advanced stage
of the disease and in metastases [6].
In addition to RTK abnormalities, the loss of endogenous regu-
lators represents an alternative mechanism that leads to aberrant
RTK activity. Sprouty (SPRY), which acts as an antagonistic regula-
tor of tracheal branching, was ﬁrst identiﬁed in Drosophila [10]. To
date, four SPRY genes (SPRY1–4) have been identiﬁed in mammals
[11]: SPRY1, SPRY2 and SPRY4 are expressed in various mouse
embryonic tissues, whereas SPRY3 is only detected in the adult
brain and testis [11,12]. Similar to Drosophila SPRY, mammalian
SPRY proteins are able to negatively regulate various growth
factors that induce RTK signaling by inhibiting the RAS/ERK1/2
pathway [13,14]. Different SPRYs have been found to be down-
regulated in several human cancers, including breast, prostate,
liver and lung cancers [15]. Functionally, SPRY has been reported
to interfere with the cell cycle, cell proliferation, migration and
invasion, in vitro and in vivo tumorigenic potential, and the forma-
tion of metastases [16–21]. Importantly, the prognostic value of
the level of SPRY has been established in renal, liver and prostate
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reliable marker of the response to Gleevec treatment for patients
with gastrointestinal stromal tumors [25]. Nonetheless, the mech-
anism by which SPRY is down-regulated appears to vary depending
on the cancer type, and contradicting data exist for similar malig-
nancies [16–19,23,24,26,27].
The present study aimed to investigate the underlying mecha-
nisms and functions of SPRY in human EOC, in addition to SPRY
down-regulation. We demonstrate that the mRNA levels of SPRY2,
but not SPRY1 or SPRY4, are signiﬁcantly down-regulated in both
human HGSC tissues and EOC cell lines. Moreover, the SPRY2 gene
is deleted in some HGSC tissues, which may, in part, cause the
down-regulation of SPRY2 levels. We further show that the overex-
pression of SPRY2 in a human ovarian cancer cell line, SKOV3,
attenuates the EGF-induced down-regulation of E-cadherin and
cell invasion. Furthermore, the protein levels of SPRY2 are posi-
tively correlated with the protein levels of E-cadherin in HGSC
tissues.
2. Materials and methods
2.1. The Human Exonic Evidence-Based Oligonucleotide (HEEBO)
microarray
The HEEBO microarray (Stanford, CA, USA) employed for this
study includes 44544 70-mer probes that were designed using
transcriptome-based annotation of the exonic structure of genomic
loci. Pooled RNA from 10 human cancer cell lines of different
origins (Stratagene, Universal Human Reference RNA, Catalog
number: 740000) for broad gene coverage on the array was
included as a reference. We examined the mRNA expression
proﬁles of a series of ovarian tumors from the Vancouver General
Hospital (Vancouver, BC, Canada) tumor bank obtained from
patients who underwent surgery in 2004 and 2005. These cases
included the following: high-grade serous (n = 35), low-grade
serous (n = 2), endometrioid (n = 7), clear cell (n = 3), serous
borderline (n = 1), endometrioid borderline tumor (n = 1) and
normal fallopian tube (n = 1) subtypes. Approval for the study
was obtained from the University of British Columbia Research
Ethics Board (#H04-60102), and written informed consent was
obtained from all participants involved in the study. The HEEBO
microarray analysis was performed as described previously [28].
2.2. Molecular inversion probe (MIP) copy number analysis
To determine whether deletion of the SPRY2 and SPRY4 genes
occurs in human ovarian tumors, an MIP copy number analysis
was performed using samples from another cohort of patients.
All women who underwent primary debulking surgery at the
Vancouver General Hospital and British Columbia Cancer Agency
in Vancouver, Canada, between January 2004 and September
2005 were invited to participate in the analysis, except those with
mucinous and borderline tumors or who had received pre-opera-
tive chemotherapy. The pathology data were reviewed by a pathol-
ogist (Dr. C. Blake Gilks). The classiﬁcation and grading of tumors
were performed as described previously [29]. We included
28 high-grade serous, 5 high-grade serous/undifferentiated, 3
high-grade undifferentiated, 5 endometrioid, 4 clear cell and 1
low-grade serous carcinomas. Ethical approval was obtained from
the University of British Columbia Research Ethics Board (#H02-
61375 and #H03-70606), and written informed consent was
obtained from all participants involved in the study. The MIP copy
number assay and copy number estimation were performed as
described previously [30]. A copy number over 3.0 was considered
an ampliﬁcation event, and a copy number below 1.5 was consid-
ered a deletion event.2.3. The cancer genome atlas (TCGA)
To obtain direct evidence that the reduced SPRY2 mRNA levels
were dependent on gene deletion, we retrieved data from the TCGA
database portal (http://cancergenome.nih.gov/). Copy number data
for 585 ovarian serous cystadenocarcinomas and 587 normal sam-
ples (569 matched and 18 unmatched) were extracted. For the
gene expression proﬁle, data from 584 tumors and 18 unmatched
normal samples were extracted.
2.4. Cell culture and reagents
Four non-tumorigenic SV40 Tag immortalized ovarian surface
epithelial cell lines (IOSEs), including IOSE-29, IOSE-80, IOSE-120,
and IOSE-398, were generous gifts from Dr. Nelly Auersperg
(University of British Columbia) [31]. The human ovarian adenocar-
cinoma cell line BG-1 was kindly provided by Dr. K.S. Korach
(National Institute of Environmental Health Sciences, NIH, Research
Triangle Park, NC, USA) [32]. The CaOV3, OVCAR3 and SKOV3 ovar-
ian cancer cell lines were obtained from American Type Culture
Collection (Manassas, VA, USA). The cell lines were cultured in
MCDB 105/M199 (1:1) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 100 IU/ml penicillin and 100 g/ml strepto-
mycin. The cells were cultured at 37 C with 5% CO2. Fetal bovine
serum was purchased from HyClone Laboratories (Logan, UT, USA).
Human recombinant EGF and other tissue culture materials were
obtained from Sigma Chemical Co. (St. Louis, MO, USA), unless other-
wise stated. To overexpress human SPRY2, the pXJ40-FLAG-SPRY2
vector and empty pXJ40-FLAG vector (gifts from Dr. Graeme R. Guy,
Institute of Molecular and Cell Biology, Singapore) [33] were transfec-
ted using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
2.5. Real-time quantitative PCR (RT-qPCR)
RT-qPCR was performed using an ABI 7300 real-time thermal
cycler (ABI, Hercules, CA, USA). SPRY1, SPRY2, SPRY4 and the inter-
nal control GAPDH were ampliﬁed in duplicate with the following
PCR primers: SPRY1, forward 50-ATG GAT CCC CAA AAT CAA CA-30
and reverse 50-CGA GGA GCA GGT CTT TTC AC-30; SPRY2, forward
50-CCC CTC TGT CCA GAT CCA TA-30 and reverse 50-CCC AAA TCT
TCC TTG CTC AG-30; SPRY4, forward 50-AGC CTG TAT TGA GCG
GTT TG-30 and reverse 50-GGT CAA TGG GTA GGA TGG TG-30,
E-cadherin, forward 50-ACA GCC CCG CCT TAT GAT T-30 and reverse
50-TCG GAA CCG CTT CCT TCA-30; SNAIL, forward 50-CCC CAA TCG
GAA GCC TAA CT-30 and reverse 50-GCT GGA AGG TAA ACT CTG
GAT TAG A-30; SLUG, forward 50-TTC GGA CCC ACA CAT TAC
CT-30 and reverse 50-GCA GTG AGG GCA AGA AAA AG-30; and
GAPDH, forward 50- GAG TCA ACG GAT TTG GTC GT-30 and reverse
50-GAC AAG CTT CCC GTT CTC AG-30.
2.6. Western blotting analysis
Equal amounts of total cell lysate were resolved on 10%
SDS–PAGE gels and electrotransferred onto a PVDF membrane.
After blocking for 1 h with 5% non-fat dry milk in TBS-T buffer
(20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20), the blots
were probed overnight at 4 C with primary antibodies. The
anti-E-cadherin antibody was obtained from BD Transduction
Laboratories (Lexington, KY, USA). The anti-SPRY2 antibody was
purchased from Sigma. The anti-SNAIL and anti-SLUG antibodies
were obtained from Cell Signaling Technology (Danvers, MA,
USA). The anti-actin antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The blots were then
incubated with a peroxidase-conjugated secondary antibody
(Bio-Rad) for 1 h, followed by detection with an ECL chemilumines-
cence reagent and exposure to X-ray ﬁlms.
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Twenty-four-well Transwell ﬁlters with an 8-lm pore size
coated with 1 mg/ml Matrigel (50 ll/well; BD Sciences,
Mississauga, ON, Canada) were used to assess cell invasion.
SKOV3 cells transfected with either control or SPRY2-overexpres-
sion constructs were trypsinized and resuspended in 0.1% FBS
medium, with or without 100 ng/ml EGF, and then seeded in
triplicate in the upper chamber. A medium containing 1% FBS
was added to the lower wells. The chambers were incubated for
24 h at 37 C in an atmosphere containing 5% CO2. The cells that
did not penetrate the ﬁlter were wiped off. The invading cells on
the lower surface of the ﬁlter were ﬁxed with ice-cold methanol,
stained with Hoechst 33258 and counted via epiﬂuorescence
microscopy with Northern Eclipse 6.0 software (Empix Imaging,
Mississauga, ON, Canada). Triplicate inserts were used for each
individual experiment, and the results are presented as the mean
numbers.
2.8. Statistical analysis
A statistical analysis was performed using Prism graphing soft-
ware. Differential variation in SPRY mRNA levels among ovarian
tumor subtypes was assessed using the Kruskal–Wallis rank test
followed by Student’s t test to compare each tumor subtype. The
relative quantiﬁcation of mRNA expression levels, as assessed by
RT-qPCR, was calculated using the 2DD Ct method. For the
invasion assay and the comparison of genes or proteins expression
levels with the control (using SPRY2-overexpressing cells), a one-
way ANOVA and non-parametric column analysis was performed
followed by Tukey’s multiple comparison test to compare all pairs
of columns. Columns with different letters are signiﬁcantly
different (P < 0.05). The data are presented as the mean ± SD of
three or four independent experiments. The Pearson correlation
coefﬁcient (r) and associated probability (P) were calculated when
comparing E-cadherin and SPRY2 protein levels using the
Spearman non-parametric correlation.Fig. 1. The box plot displays the HEEBO microarray results for SPRY2 mRNA levels in hu
endometrioid (n = 7), clear cell (n = 3), serous borderline (n = 1), endometrioid borderline
cell lines of different origins for broad gene coverage on the array was included as a ref3. Results
3.1. Levels of SPRY mRNA in different pathological subtypes of human
EOC
To examine whether the mRNA levels of SPRY isoforms are
down-regulated in human EOC, we compared EOC samples of
various histopathological subtypes, including serous (high-grade,
low-grade or borderline), endometrioid (carcinoma or borderline
tumor) and clear cell subtypes. The results of the HEEBO micro-
array analysis showed no signiﬁcant differences for the mRNA
levels of three different SPRY1 transcripts in each subtype
(Kruskal–Wallis test, P = 0.396, 0.706 and 0.813). Similarly, SPRY4
mRNA levels were not signiﬁcantly different between the subtypes
(P = 0.33). Interestingly, signiﬁcant differences in the SPRY2 mRNA
levels were observed in various tumors types (P = 0.0091). The
lowest mean level of SPRY2 mRNA was observed in the clear cell
subtype, followed by HGSC; all other samples displayed higher
mean SPRY2 mRNA levels compared with the reference level
(Fig. 1). When comparing pathological subtypes, the difference in
SPRY2 mRNA levels between high-grade and low-grade serous
subtypes was statistically signiﬁcant (P = 0.022). The mean SPRY2
mRNA levels in serous and clear cell carcinomas were statistically
lower than that of endometrioid carcinomas (serous vs. endometri-
oid, P = 0.0007; clear cell vs. endometrioid, P = 0.022).
3.2. Levels of SPRY mRNA in cultured human EOC cell lines
Next, we examined SPRY mRNA levels in four human EOC cell
lines (BG-1, CaOV3, OVCAR3 and SKOV3) by RT-qPCR. Four immor-
talized human ovarian surface epithelial cell lines (IOSEs) estab-
lished from individual patients were included for comparison. As
shown in Fig. 2, our results showed that the mRNA level of SPRY1
was higher in all human EOC cell lines compared with the IOSE cell
lines and that the SPRY4 level was consistently lower in the EOC
cell lines. Down-regulated SPRY2 mRNA levels were detected in
three out of four human EOC cell lines.man EOC of various subtypes: high-grade serous (n = 35), low-grade serous (n = 2),
tumors (n = 1) and normal fallopian tube (n = 1). Pooled RNA from 10 human cancer
erence (0). Dots represent individual samples.
Fig. 2. Comparison of SPRY1, SPRY2 and SPRY4 mRNA levels, as measured by RT-qPCR, in human immortalized OSE (IOSE) and EOC cell lines. The SPRY1, SPRY2 and SPRY4
mRNA levels were normalized against the internal control GAPDH. The average normalized expression levels of SPRY1, SPRY2 and SPRY4 in the IOSE cell lines were calculated
and set to 100%. The relative levels of SPRY1 (A), SPRY2 (B) and SPRY4 (C) mRNA levels in EOC cell lines are expressed as a percentage of their mean expression in IOSE cell
lines. The results are expressed as the means ± SD of three independent experiments from three passages.
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An MIP copy number analysis was performed to examine to the
occurrence of chromosomal changes in the human SPRY2 and
SPRY4 genes. Because there are no speciﬁc intragenic probes avail-
able, we used probes closely ﬂanking the SPRY2 and SPRY4 loci as
surrogate markers. Among the 46 EOC tissues analyzed, two mark-
ers tightly ﬂanking the SPRY2 locus (MIP ID: 437874 and MIP ID:
440961) revealed loss in 23.4% (11/46) and 19.6% (9/46), respec-
tively, of the samples. Notably, such deletion events were most fre-
quent in HGSC, with frequencies of 32.1% (9/28) to 35.7% (10/28)
(Fig. 3). Conversely, none of the endometrioid, clear cell, or low-
grade serous tumors exhibited SPRY2 gene deletion (Table 1).
Two additional markers (MIP ID: 437922 and MIP ID: 442871)
revealed similar frequencies of loss (25% and 35.7%, respectively)Fig. 3. A schematic representation of the MIP copy number assay results for 28
high-grade serous ovarian carcinomas. The diagram shows the MIP ID, distance to
the SPRY locus and corresponding percentage of the loss of markers ﬂanking the
SPRY2 locus (left panel) and markers ﬂanking the SPRY4 locus (right panel).in HGSC (Fig. 3). In contrast, the deletion of the markers closest
to the SPRY4 locus (MIP ID: 431289 and MIP ID: 439693) was rarely
found in HGSC, with deletion only found in 3.6% (1/28) and 7.1% (2/
28), respectively, of the samples (Fig. 3). Two markers more distant
from the SPRY4 gene (MIP ID: 431174 and MIP ID: 448347)
revealed only 7.1% (2/28) and 3.6% (1/28) loss, respectively
(Fig. 3). In a TCGA data set, 24% of the ovarian serous cystadenocar-
cinoma samples displayed a decrease in gene copy number, and a
majority (67%) of these samples showed a decrease in the SPRY2
mRNA level. In contrast, 54% of the ovarian tumors in the TCGA
gene expression analysis showed a decrease in the SPRY2 level,
though only 32% of these tumors also showed a decrease in copy
number. Taken together, these results indicated that SPRY2 gene
deletion might, in part, contribute to reduced SPRY2 expression
and also suggested that additional mechanisms might contribute
to reduced SPRY2 expression in HGSC.
3.4. Overexpression of SPRY2 attenuates EGF-induced down-regulation
of E-cadherin and up-regulation of SNAIL in human ovarian cancer
cells
Our previous studies have shown EGF-induced cell invasion via
the ERK1/2-mediated down-regulation of E-cadherin in the human
ovarian cancer cell line SKOV3 [34,35]. Given the important role of
SPRY2 in the regulation of ERK1/2 signaling, we examined the
function of SPRY2 in EGF-induced down-regulation of E-cadherin
and cell invasion. As shown in Fig. 4A, consistent with our previous
results, treatment of SKOV3 cells with 100 ng/ml EGF for 24 h sig-
niﬁcantly down-regulated E-cadherin mRNA levels. Interestingly,
SPRY2 overexpression did not affect basal E-cadherin mRNA levels
but did attenuate the down-regulation induced by EGF treatment
(Fig. 4A). Similarly, Western blotting results showed that
treatment with 100 ng/ml EGF for 24 h down-regulated E-cadherin
protein levels and that SPRY2 overexpression attenuated the
EGF-induced down-regulation of E-cadherin protein levels
(Fig. 4B). It has been well characterized that the down-regulation
Table 1
MIP analysis of loss of markers ﬂanking SPRY2 and SPRY4 loci in ovarian tumors.
Number Histopathology SPRY2 SPRY4
Proximal 2 Proximal 1 Distal 1 Distal 2 Proximal Distal
223 Serous HG 1.40 1.40 1.58 1.58 2.09 1.92
329 Serous HG 1.37 1.20 1.26 1.26 1.44 1.33
293 Serous HG 1.94 1.88 1.88 1.88 2.10 2.22
283 Serous HG 1.44 1.09 1.30 1.30 2.43 2.13
239 Serous HG 2.41 2.24 2.28 2.28 2.42 2.31
327 Serous HG 2.26 1.98 2.49 2.13 2.31 2.07
379 Serous HG 1.58 1.58 1.41 1.36 2.09 2.09
163 Serous HG 1.46 1.43 1.44 1.44 1.77 1.99
305 Serous HG 2.09 2.09 1.94 1.94 2.61 2.32
212 Serous HG 1.54 2.76 1.54 2.12 1.83 2.36
330 Serous HG 2.34 2.17 2.57 2.56 1.56 1.41
332 Serous HG 2.08 1.69 1.30 1.30 2.12 1.77
388 Serous HG 2.97 2.97 3.01 2.56 2.05 1.94
363 Serous HG 1.57 1.36 1.36 1.32 2.21 2.27
344 Serous HG 2.06 1.57 2.26 1.74 2.73 2.44
345 Serous HG 1.29 1.28 1.18 1.18 2.47 2.91
384 Serous HG 1.93 1.82 1.97 1.74 2.71 2.36
178 Serous HG 2.04 2.02 2.02 1.57 2.67 2.35
229 Serous HG 1.35 1.35 1.53 1.46 2.26 2.10
309 Serous HG 2.36 2.36 2.45 2.21 2.23 2.23
394 Serous HG 1.96 1.83 1.83 1.82 2.22 2.09
195 Serous HG 1.75 1.24 1.20 1.20 2.39 2.39
236 Serous HG 1.42 1.42 1.53 1.53 1.59 1.90
172 Serous HG 2.75 2.22 2.13 1.99 1.62 1.55
254 Serous HG 1.68 1.68 1.75 1.84 2.05 2.05
319 Serous HG 2.51 2.16 2.30 2.30 2.15 2.21
372 Serous HG 1.50 1.36 1.36 1.30 2.35 2.41
297 Serous HG 2.03 2.00 2.09 1.86 2.27 2.19
208 Undifferentiated HG 3.03 2.53 2.72 2.72 1.81 1.81
273 Undifferentiated HG 1.67 1.48 1.54 1.54 1.94 1.66
240 Undifferentiated HG 2.27 2.10 2.27 2.30 2.10 2.02
161 Serous/undifferentiated HG 1.87 1.72 1.67 1.67 1.87 1.82
336 Serous/undifferentiated HG 1.88 2.27 1.83 1.83 1.87 1.87
186 Serous/undifferentiated HG 2.44 2.09 2.09 2.36 2.60 2.72
201 Serous/undifferentiated HG 2.23 2.23 1.81 1.81 3.24 3.24
280 Serous/undifferentiated HG 2.62 2.57 2.54 2.54 1.89 2.25
198 Clear cell 2.18 2.01 2.23 1.88 3.04 2.42
213 Clear cell 2.14 2.14 1.86 1.86 2.01 1.98
219 Clear cell 2.48 2.50 2.61 2.61 2.26 2.07
392 Clear cell 2.04 1.81 2.04 1.64 2.54 2.31
242 Endometrioid – G2 2.37 2.02 2.37 1.91 2.58 2.14
281 Endometrioid – G2 2.23 2.41 2.45 2.45 2.23 2.23
334 Endometrioid – G1 2.02 1.94 2.32 2.23 2.35 1.92
156 Endometrioid – G2 1.93 1.93 1.90 1.90 2.18 1.88
343 Endometrioid – G2 2.46 2.03 2.03 2.03 2.26 2.33
324 Serous LG 2.00 1.97 2.00 2.00 1.92 2.13
MIP analysis were performed on 28 high-grade serous, 5 high-grade serous/undifferentiated, 3 high-grade undifferentiated, 5 endometrioid, 4 clear cell and 1 low-grade
serous ovarian tumors to detect presence of the marker ﬂanking the SPRY2 and SPRY4 loci. The MIP copy numbers below 1.5 were considered deletion events (bolded). HG:
high-grade; LG: low-grade; G1: grade 1; G2: grade 2; G3: grade 3.
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SLUG-mediated transcriptional suppression [36]. As shown in
Fig. 4C, treatment with 100 ng/ml EGF for 3 h signiﬁcantly up-reg-
ulated SNAIL and SLUG mRNA levels, whereas the overexpression
of SPRY2 did not affect the basal mRNA levels of SNAIL and SLUG.
Interestingly, SPRY2 overexpression only attenuated the
EGF-induced up-regulation of SNAIL mRNA levels but not those
of SLUG (Fig. 4C). Similarly, treatment with 100 ng/ml EGF for 3 h
signiﬁcantly up-regulated SNAIL and SLUG protein levels, and the
overexpression of SPRY2 attenuated the EGF-induced up-regula-
tion of SNAIL protein levels but not those of SLUG (Fig. 4D).
3.5. Overexpression of SPRY2 attenuates EGF-induced human ovarian
cancer cell invasion
We have shown that EGF treatment induces human ovarian
cancer cell invasion by down-regulating E-cadherin expression
and that E-cadherin overexpression blocks EGF-induced humanovarian cancer cell invasion [34,35,37,38]. Because the overexpres-
sion of SPRY2 attenuated the EGF-induced down-regulation of
E-cadherin, we next examined whether it could also affect
EGF-induced ovarian cancer cell invasion. As shown in Fig. 5,
SPRY2 overexpression attenuated EGF-induced cell invasion
without affecting basal cell invasiveness.
3.6. SPRY2 expression levels are positively correlated with the
expression levels of E-cadherin in human EOC
To further examine the correlation between SPRY2 and E-cad-
herin, we analyzed the protein levels of SPRY2 and E-cadherin in
eleven HGSC tissues isolated from patients. As shown in Fig. 6A,
the SPRY2 and E-cadherin proteins were detected in the majority
of samples by the results of Western blotting. In addition, the
results of a Spearman non-parametric correlation analysis revealed
a statistically signiﬁcant positive correlation (Pearson correlation
coefﬁcient, r = 0.6620 and P = 0.0265) (Fig. 6B).
Fig. 4. The effect of SPRY2 overexpression on EGF-induced up-regulation of SNAIL
and SLUG and down-regulation of E-cadherin. (A) and (B) SKOV3 cells were
transfected with the empty pXJ40-FLAG vector (Vector) or SPRY2-overexpression
pXJ40-FLAG-SPRY2 vector (SPRY2) for 48 h and then treated with vehicle control
(Ctrl) or 100 ng/ml EGF for 24 h. The mRNA (A) and protein (B) levels of E-cadherin
and SPRY2 were analyzed by RT-qPCR and Western blotting, respectively. (C) and
(D) SKOV3 cells were transfected with the empty pXJ40-FLAG vector (Vector) or
SPRY2-overexpression pXJ40-FLAG-SPRY2 vector (SPRY2) for 48 h and then treated
with vehicle control (Ctrl) or 100 ng/ml EGF for 3 h. The mRNA (C) and protein (D)
levels of SNAIL, SLUG and SPRY2 were analyzed by RT-qPCR and Western blotting,
respectively. The results are expressed as the mean ± SEM from at least three
independent experiments. Values without a common letter are signiﬁcantly
different (P < 0.05).
Fig. 5. The effect of SPRY2 overexpression on EGF-induced human ovarian cancer
cell invasion. SKOV3 cells were transfected with the empty pXJ40-FLAG vector
(Vector) or SPRY2-overexpression vector pXJ40-FLAG-SPRY2 (SPRY2) for 48 h. The
cells were treated with vehicle control (Ctrl) or 100 ng/ml EGF and then seeded into
Matrigel-coated Transwell inserts and cultured for an additional 24 h. Non-invading
cells were removed from the upper side of the ﬁlter, and the nuclei of the invaded
cells were stained with Hoechst 33258. The top panel shows representative
ﬂuorescence images from the invasion assay. The bottom panel summarizes the
quantitative results, which are expressed as the mean ± SEM from three indepen-
dent experiments. Values with different letters are signiﬁcantly different (P < 0.05).
Fig. 6. The correlation between SPRY2 and E-cadherin protein levels in human EOC
tissues. (A) The protein levels of E-cadherin and SPRY2 in eleven high-grade serous
ovarian carcinomas were analyzed by Western blotting. (B) The protein expression
levels of E-cadherin and SPRY2 were quantiﬁed, and correlations were assessed
using the Spearman non-parametric correlation method.
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SPRY proteins have been identiﬁed as endogenous inhibitors of
the RAS/ERK1/2 pathway downstream of RTKs. As the aberrant
activity of various RTKs, especially EGFR, plays an important role
in the tumorigenesis of human EOC, the present study aimed to
examine the expression proﬁle and function of SPRY isoforms in
human EOC. Our results demonstrated no signiﬁcant differences
in the mRNA levels of SPRY1 and SPRY4 in different human EOC
subtypes. However, the mRNA levels of SPRY2 were signiﬁcantly
decreased in HGSC tissues and human EOC cell lines. In addition,
the results of our MIP analysis suggested that deletions in the
SPRY2 gene may be an important factor involved in SPRY2 down-
regulation in HGSC. Moreover, we demonstrated that the expres-
sion levels of SPRY2 and E-cadherin were positively correlated in
HGSC and that the overexpression of SPRY2 attenuated the EGF-
induced up-regulation of SNAIL, which, in turn, contributed to
the attenuation of the EGF-induced down-regulation of E-cadherin
and cell invasion.Recently, it has been shown that both SPRY1 and SPRY2 mRNA
and protein are present in seven different human EOC cell lines.
Interestingly, compared to normal OSE cells, four of the seven
EOC cell lines exhibited lower SPRY1 and SPRY2 mRNA levels
[39]. The results for SPRY2 mRNA are similar to our results, though
the results for SPRY1 mRNA are different. In our study, instead of
308 W.-K. So et al. / FEBS Letters 589 (2015) 302–309using normal OSE as an experimental control, we used four SV40
Tag immortalized OSE cell lines as our experimental control. Thus,
it is possible that the divergent results are due to the use of two
different control cells. The OSE has generally been considered to
be the site of cell origin for human EOC [40]. However, recent stud-
ies have shown that the fallopian tubes may be where HGSC arises,
leading to the current controversy over whether human EOC arises
from the OSE or oviductal epithelial cells [41,42]. The results of our
HEEBO microarray showed that the SPRY2 mRNA level was lower
in HGSC than in the microarray reference. Importantly, although
we only included one normal fallopian tube tissue sample, the
SPRY2mRNA level in HGSC was lower than that in normal fallopian
tube tissue. Therefore, our results together with previous studies
demonstrate that SPRY2 mRNA levels are down-regulated in HGSC.
The human SPRY2 locus has been mapped to 13q31.1 [26], and
previous cytogenetic studies have shown that chromosomal loss of
either 13 or 13q is a frequent event in both hereditary and sporadic
ovarian carcinomas [43–46]. This frequency can be explained by
the existence of known tumor suppressor genes on 13q, including
BRCA2 (13q12-13), RB (13q14) and protocadherin 9 (13q21-2). Our
MIP copy number analysis results revealed the chromosomal dele-
tion of the human SPRY2 locus mainly in HGSC and not in other
subtypes. In the TCGA database, 16% of serous cystadenocarcino-
mas showed both gene deletion and reduced mRNA expression of
SPRY2. These results supported our ﬁnding that SPRY2 mRNA lev-
els are down-regulated in HGSC and that gene deletion is one of
the important factors causing this genetic alteration.
It is interesting to note that according to our TCGA gene expres-
sion analysis, only 32% of tumors with down-regulated SPRY2
mRNA levels exhibited a gene deletion. These results strongly indi-
cate that additional mechanisms are involved in the down-regula-
tion of SPRY2 mRNA levels. Indeed, the presence of CpG islands in
the SPRY2 50 regulatory region suggests the potential involvement
of epigenetic mechanisms in the regulation of SPRY2 expression
[26]. In both human prostate and liver cancers, down-regulated
SPRY2 expression is observed in cancer cell lines and tumor tissues.
However, whether SPRY2 promoter hypermethylation contributes
to the down-regulation of SPRY2 in human prostate and liver can-
cers remains controversial [16,23,24,26]. To date, it is unclear
whether epigenetic alterations affect the expression levels of
SPRY2 in human EOC. Therefore, future studies will be necessary
to investigate the status of SPRY2 promoter methylation and its
contribution to the down-regulation of SPRY2 mRNA levels in
HGSC.
To the best of our knowledge, the functions of the SPRY protein
in human EOC progression remain largely unknown. Only one
recent study has shown that SPRY1 overexpression in SKOV3 cells
reduces cell proliferation, migration and invasion [47]. We have
previously shown that EGF induces SKOV3 cell invasion by
down-regulating E-cadherin expression [34,35]. In the present
study, we found that the overexpression of SPRY2 in SKOV3 cells
did not affect the basal levels of SNAL, SLUG, E-cadherin expression
or cell invasiveness. However, the EGF-induced up-regulation of
SNAIL, the down-regulation of E-cadherin and increased cell inva-
sion were attenuated by the overexpression of SPRY2. In addition,
our results also revealed a positive correlation between SPRY2 and
E-cadherin in human EOC tissues. In contrast to our results, SPRY2
has been shown to repress both basal and 1a,25-dihydroxyvitamin
D3-induced E-cadherin expression in human colon cancer cells by
up-regulating the expression of ZEB1, a transcriptional repressor of
E-cadherin [48]. Moreover, the expression levels of SPRY2 and E-
cadherin have been shown to be inversely correlated in human
colon cancer cell lines and xenografted tumors [48]. These results
indicate that the roles of SPRY2 in the regulation of cancer progres-
sion are cancer type speciﬁc.Our previous studies have shown that SNAIL and SLUG are two
major E-cadherin transcriptional repressors that mediate the EGF-
induced down-regulation of E-cadherin [34,35,37,38]. In addition,
our previous study demonstrates that the ERK1/2 and PI3k/Akt sig-
naling pathways are involved in EGF-induced SNAIL and SLUG
expression, whereas the p38 MAPK signaling pathway only medi-
ates EGF-induced SNAIL, but not SLUG, expression in human ovar-
ian cancer cells [34]. SPRY proteins are well characterized as
negative feedback regulators of the RAS/ERK1/2 signaling pathway.
However, a recent study demonstrates that SPRY proteins are also
able to regulate the activation of p38 MAPK signaling [49]. In
mouse embryonic ﬁbroblast cells, targeted disruption of the SPRY1,
SPRY2 and SPRY4 genes enhances the interferon-induced activation
of p38 MAPK, though the precise protein target of SPRY proteins
among the components of the IFN-activated p38 MAPK pathway
remain to be determined [49]. These results suggest that the over-
expression of SPRY2 observed in the present study might have
affected EGF-induced p38 MAPK activation, which, in turn, specif-
ically attenuated the EGF-induced up-regulation of SNAIL but not
SLUG. However, details of the molecular mechanisms regarding
this regulation remain to be directly addressed in future studies.
In summary, the present study demonstrates that SPRY2 mRNA
levels are down-regulated in HGSC, which may, in part, be caused
by chromosomal deletions. The overexpression of SPRY2 reduces
EGF-induced cell invasiveness by attenuating the EGF-induced
down-regulation of E-cadherin expression. These results indicate
that SPRY2 acts as a tumor suppressor in HGSC. Further clariﬁca-
tion of the mechanisms underlying SPRY function and regulation
will not only advance our understanding of human EOC progres-
sion but will also facilitate the development of novel therapeutic
strategies.
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